AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data
In competition with Boehringer And Lilly’s Jardiance
AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.
